Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting

Joseph W. Romano, Marc M. Baum, Zach R. Demkovich, Frank DIana, Charles Dobard, Paul L. Feldman, J. Gerardo Garcia-Lerma, Alessandro Grattoni, Manjula Gunawardana, Duy Khiet Ho, Thomas J. Hope, Ivana Massud, Mark Milad, John A. Moss, Fernanda P. Pons-Faudoa, Shane Roller, Ariane Van Der Straten, Selvi Srinivasan, Ronald S. Veazey, Doris Zane

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


The ability to successfully develop a safe and effective vaccine for the prevention of HIV infection has proven challenging. Consequently, alternative approaches to HIV infection prevention have been pursued, and there have been a number of successes with differing levels of efficacy. At present, only two oral preexposure prophylaxis (PrEP) products are available, Truvada and Descovy. Descovy is a newer product not yet indicated in individuals at risk of HIV-1 infection from receptive vaginal sex, because it still needs to be evaluated in this population. A topical dapivirine vaginal ring is currently under regulatory review, and a long-acting (LA) injectable cabotegravir product shows strong promise. Although demonstrably effective, daily oral PrEP presents adherence challenges for many users, particularly adolescent girls and young women, key target populations. This limitation has triggered development efforts in LA HIV prevention options. This article reviews efforts supported by the Bill & Melinda Gates Foundation, as well as similar work by other groups, to identify and develop optimal LA HIV prevention products. Specifically, this article is a summary review of a meeting convened by the foundation in early 2020 that focused on the development of LA products designed for extended delivery of tenofovir alafenamide (TAF) for HIV prevention. The review broadly serves as technical guidance for preclinical development of LA HIV prevention products. The meeting examined the technical feasibility of multiple delivery technologies, in vivo pharmacokinetics, and safety of subcutaneous (SC) delivery of TAF in animal models. Ultimately, the foundation concluded that there are technologies available for long-term delivery of TAF. However, because of potentially limited efficacy and possible toxicity issues with SC delivery, the foundation will not continue investing in the development of LA, SC delivery of TAF products for HIV prevention.

Original languageEnglish (US)
Pages (from-to)409-420
Number of pages12
JournalAIDS Research and Human Retroviruses
Issue number6
StatePublished - Jun 2021


  • HIV PrEP
  • TAF
  • long-acting

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases


Dive into the research topics of 'Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting'. Together they form a unique fingerprint.

Cite this